Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice
Systemic mastocytosis is a heterogeneous disease characterized by the accumulation of neoplastic mast cells in the bone marrow and other organ organs/tissues. Mutations in KIT, most frequently KIT D816V, are detected in over 80% of all systemic mastocytosis patients. While most systemic mastocytosis...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
October 2016
|
| In: |
Haematologica
Year: 2016, Jahrgang: 101, Heft: 10, Pages: 1133-1143 |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.2016.146563 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.3324/haematol.2016.146563 Verlag, Volltext: http://www.haematologica.org/content/101/10/1133 
|
| Verfasserangaben: | Celalettin Ustun, Michel Arock, Hanneke C. Kluin-Nelemans, Andreas Reiter, Wolfgang R. Sperr, Tracy George, Hans-Peter Horny, Karin Hartmann, Karl Sotlar, Gandhi Damaj, Olivier Hermine, Srdan Verstovsek, Dean D. Metcalfe, Jason Gotlib, Cem Akin, and Peter Valent |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1586428233 | ||
| 003 | DE-627 | ||
| 005 | 20230427034209.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190121s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.2016.146563 |2 doi | |
| 035 | |a (DE-627)1586428233 | ||
| 035 | |a (DE-576)516428233 | ||
| 035 | |a (DE-599)BSZ516428233 | ||
| 035 | |a (OCoLC)1341033902 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Celalettin, Ustun |e VerfasserIn |0 (DE-588)1175916501 |0 (DE-627)1047041588 |0 (DE-576)516427989 |4 aut | |
| 245 | 1 | 0 | |a Advanced systemic mastocytosis |b from molecular and genetic progress to clinical practice |c Celalettin Ustun, Michel Arock, Hanneke C. Kluin-Nelemans, Andreas Reiter, Wolfgang R. Sperr, Tracy George, Hans-Peter Horny, Karin Hartmann, Karl Sotlar, Gandhi Damaj, Olivier Hermine, Srdan Verstovsek, Dean D. Metcalfe, Jason Gotlib, Cem Akin, and Peter Valent |
| 264 | 1 | |c October 2016 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 21.01.2019 | ||
| 520 | |a Systemic mastocytosis is a heterogeneous disease characterized by the accumulation of neoplastic mast cells in the bone marrow and other organ organs/tissues. Mutations in KIT, most frequently KIT D816V, are detected in over 80% of all systemic mastocytosis patients. While most systemic mastocytosis patients suffer from an indolent disease variant, some present with more aggressive variants, collectively called “advanced systemic mastocytosis”, which include aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic, clonal non mast cell-lineage disease, and mast cell leukemia. Whereas patients with indolent systemic mastocytosis have a near normal life expectancy, patients with advanced systemic mastocytosis have a reduced life expectancy. Although cladribine and interferon-alpha are of benefit in a group of patients with advanced systemic mastocytosis, no curative therapy is available for these patients except possible allogeneic hematopoietic stem cell transplantation. Recent studies have also revealed additional somatic defects (apart from mutations in KIT) in a majority of patients with advanced systemic mastocytosis. These include TET2, SRSF2, ASXL1, RUNX1, JAK2, and/or RAS mutations, which may adversely impact prognosis and survival in particular systemic mastocytosis with an associated hematological neoplasm. In addition, several additional signaling molecules involved in the abnormal proliferation of mast cells in systemic mastocytosis have been identified. These advances have led to a better understanding of the biology of advanced systemic mastocytosis and to the development of new targeted treatment concepts. Herein, we review the biology and pathogenesis of advanced systemic mastocytosis, with a special focus on novel molecular findings as well as current and evolving therapeutic options. | ||
| 700 | 1 | |a Reiter, Andreas |d 1964- |e VerfasserIn |0 (DE-588)172629551 |0 (DE-627)697563766 |0 (DE-576)133488594 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica |d Pavia : Ferrata Storti Foundation, 2014 |g 101(2016), 10, Seite 1133-1143 |h Online-Ressource |w (DE-627)814204899 |w (DE-600)2805244-4 |w (DE-576)424051125 |x 1592-8721 |7 nnas |a Advanced systemic mastocytosis from molecular and genetic progress to clinical practice |
| 773 | 1 | 8 | |g volume:101 |g year:2016 |g number:10 |g pages:1133-1143 |g extent:11 |a Advanced systemic mastocytosis from molecular and genetic progress to clinical practice |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3324/haematol.2016.146563 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.haematologica.org/content/101/10/1133 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190121 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 172629551 |a Reiter, Andreas |m 172629551:Reiter, Andreas |d 60000 |d 61200 |e 60000PR172629551 |e 61200PR172629551 |k 0/60000/ |k 1/60000/61200/ |p 4 | ||
| 999 | |a KXP-PPN1586428233 |e 3046139268 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 21.01.2019"],"recId":"1586428233","name":{"displayForm":["Celalettin Ustun, Michel Arock, Hanneke C. Kluin-Nelemans, Andreas Reiter, Wolfgang R. Sperr, Tracy George, Hans-Peter Horny, Karin Hartmann, Karl Sotlar, Gandhi Damaj, Olivier Hermine, Srdan Verstovsek, Dean D. Metcalfe, Jason Gotlib, Cem Akin, and Peter Valent"]},"relHost":[{"note":["Gesehen am 27.05.2022"],"pubHistory":["99.2014 -"],"recId":"814204899","disp":"Advanced systemic mastocytosis from molecular and genetic progress to clinical practiceHaematologica","part":{"extent":"11","year":"2016","issue":"10","volume":"101","text":"101(2016), 10, Seite 1133-1143","pages":"1133-1143"},"titleAlt":[{"title":"journal of the European Hematology Association"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Haematologica","subtitle":"journal of the European Hematology Association : journal of the Ferrata Storti Foundation","title":"Haematologica"}],"id":{"eki":["814204899"],"zdb":["2805244-4"],"issn":["1592-8721"]},"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"Ferrata Storti Foundation","dateIssuedKey":"2014","dateIssuedDisp":"2014-","publisherPlace":"Pavia"}]}],"person":[{"role":"aut","given":"Ustun","display":"Celalettin, Ustun","family":"Celalettin"},{"given":"Andreas","display":"Reiter, Andreas","family":"Reiter","role":"aut"}],"physDesc":[{"extent":"11 S."}],"title":[{"title_sort":"Advanced systemic mastocytosis","subtitle":"from molecular and genetic progress to clinical practice","title":"Advanced systemic mastocytosis"}],"origin":[{"dateIssuedDisp":"October 2016","dateIssuedKey":"2016"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.3324/haematol.2016.146563"],"eki":["1586428233"]},"language":["eng"]} | ||
| SRT | |a CELALETTINADVANCEDSY2016 | ||